The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 – 6. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including multicenter, international trials in collaboration with leading cancer institutions, such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, Cleveland Clinic and Memorial Sloan Kettering. ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and bone marrow stem cell transplantation, sickle cell, leukemia, and myelodysplastic syndromes.

"We have a long-standing commitment to expand our research capabilities, which includes investing in clinical and research talent, new technology, and infrastructure improvements. As a result, we are presenting twice as many studies compared to last year at this premier hematology conference," said Andre Goy, M.D., M.S., deputy director, director of clinical and translational research, and chief of lymphoma of the John Theurer Cancer Center. "Furthermore, six investigators were first authors of 13 studies, including multicenter trials, establishing our leadership role in the fight against cancer."

In January 2011, the John Theurer Cancer Center will begin treating patients in a new building that will allow the cancer center to further expand its commitment to research and innovation. Breakthrough advances being pioneered in this new facility will include a dedicated Phase 1 Unit, tumor banking to help development of biomarkers as part of next generation clinical trials, new state-of-the-art radiotherapy systems, and functional imaging.

Lead authors presenting at ASH from the John Theurer Cancer Center include Dr. Goy; David Siegel, M.D. , co-chief, multiple myeloma; David Vesole, M.D., co-chief and research director, multiple myeloma; Stuart Goldberg, M.D., chief, leukemia; Anthony R. Mato, M.D., attending, lymphoma; and Jenny Zilberberg, Ph.D., associate, research.

"We are thankful to the hundreds of patients who participated in these clinical trials, which allows us to study some of the most promising cancer-treatment candidates in the pipeline," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer and professor and vice president of cancer services, the John Theurer Cancer Center. "Their contribution is essential as our researchers and clinicians endeavor to advance treatment and develop new therapies in this fight against cancer."

John Theurer Cancer Center 2010 ASH Abstract Highlights

The following are key abstracts being presented at ASH from the John Theurer Cancer Center. For a complete list of the 40 abstracts and ongoing updates, please visit jtcancercenter.org/ash2010.

Blood and Marrow Stem Cell Transplantation

• 38: Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial Siegel D., Vesole D., et al. Oral Session: December 6, 2010 Time: 11:45am
• 366: Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation Switzer G., Rowley S., et al. Oral Session: December 6, 2010 Time: 11:45am
• 4288: Successful Implementation of GM-CSF Cellular Immunotherapy for the Treatment of Multiple Myeloma In a Mouse Model of Autologous Bone Marrow Transplantation Ziberberg J., Stein J., Friedman T., and Korngold R. Poster Session: December 6, 2010 Time: 6:00pm – 8:00pm
• 521: Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy Fowler D., Rowley S., Donato M., Goy A., Friedman T., Korngold R., Pecora A., et al. Oral Session: December 6, 2010 Time: 3:45 pm (in collaboration as sole institution with the National Cancer Institute)

Multiple Myeloma

• 308: Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD) Vesole D., Siegel D., et al. Oral Session: December 6, 2010 Time: 7:15am
• 985: Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM) Siegel D., et al. Oral Session: December 7, 2010 Time: 7:30am
• 1952: Vorinostat Combined with Bortezomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program Siegel D., et al. Poster Session December 4, 2010 Time: 5:30pm – 7:30pm
• 3017: Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma: A URCC/ECOG Phase III Study Vesole D., et al. Poster Session: December 5, 2010 Time: 6:00pm – 8:00pm
• 3065: Vorinostat Overcomes Lenalidomide –Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance in Relapsed/Refractory Multiple Myeloma Siegel D., McBride L., Bilotti E., Schmidt L., McNeill A., Donadio K., Olivo K., Bendarz U., Vesole D., et al. Poster Session: December 5, 2010 Time: 6:00pm – 8:00pm

Lymphoma

• 426: A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells Caicedo-Carvahal C., Goy A., Pecora A., Mato A., Feldman T., Suh S. Oral Session: December 6, 2010 Time: 11:45am
• 430: Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial Goy A., Feldman T., et al. Oral Session: December 6, 2010 Time: 11:15am
• 1753: Pralatrexate is Effective in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens Goy A., et al. Poster Session: December 4, 2010 Time: 5:30pm – 7:30pm
• 1782: R-HCVAD/R-MTX-Arac (R-HCVAD) Overcomes Risk Features Associated with Inferior Outcomes in the Treatment of Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Mato A., Feldman T., Zielonka T., Bhattacharyya P., Campaiola A., Shah R., Rosario M., Bejot C., Stives S., Curtin M., Vicioso R., Goldberg S., Pecora A., and Goy A. Poster Session: December 4, 2010 Time: 5:30pm – 7:30 pm
• 3131: Post-Treatment (not interim) PET-CT Scan Status is Highly Predictive of Outcome in Mantle Cell Lymphoma Treated with R-Hypercvad or ASCT Mato, A., Zielonka T., Feldman T.,Agress H., Panush D., Miller M., Toth P., Lizott Jr. P., Rowley S., Donato M., Goldberg S., Pecora A., Goy A., et al. Poster Session: December 5, 2010 Time: 6:00pm – 8:00pm
• Mantle Cell Lymphoma Goy A. Meet-the-Experts Session: December 5, 2010 Time: 11:00 am

Leukemia

• 3273: Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor in Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) Goldberg S., et al. Poster Session: December 6, 2010 Time: 6:00pm – 8:00pm
• 3453: One-Year Post-Transplant Serum Ferritin Level Is a Predictor of Long-Term Survival Following Allogeneic Transplantation Goldberg S., Elmann M., Kaminetzky M., Sidhom E., Mato A., Shah J., Stanislaus G., Limor S., Weinstein A., Jones E., Granholm K., Marrero W., Szyperek K., Polanco A., Yaniga J., Hanrahan M., Amatucci T., Sutherland P., McKiernan P., Pecora A., Donato M., and Rowley S. Poster Session: December 6, 2010 Time: 6:00pm – 8:00pm

Personalized Medicine and Hematologic Malignancies

• Moving Towards Personalized Medicine in Hematologic Malignancies, Goy A. Symposia: Peabody Orlando Hotel, Plaza International Ballroom DEF at December 3, 2010 Time: 12:30 pm - 4:30 pm

Source: John Theurer Cancer Center